Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

Answers from the Lab

English - April 30, 2024 06:00 - 14 minutes - 20.4 MB
Medicine Health & Fitness Science laboratory medicine healthcare answers from the lab mayo clinic laboratories lab mayo clinic clinical dlmp morice pritt Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Alzheimer’s Disease and Testing Innovations: Bill Morice, M.D., Ph.D.

Next Episode: The Growing Crisis of Antimicrobial Resistance: Robin Patel, M.D.

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.

(00:31)
Could you please provide a little bit about yourself and your background?

(01:30)
Would you please share a brief overview of the UBA1Q assay?

(02:13)
Would you provide an overview of VEXAS syndrome?

(05:30)
When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?

(06:38)
What advantage does this assay provide over other methodologies?

(10:13)
Could you share further why diagnosis is so important for these patients?

(12:40)
Is there anything else you'd like to comment about the assay?